

Embargoed until 7 a.m. on August 4, 2015

Key Financial Data: Second quarter/first half 2015

August 4, 2015

## Evonik raises outlook for the year following another strong quarterly result

**Tim Lange**  
Head of Investor Relations  
Phone +49 201 177-3150  
tim.lange@evonik.com

### Key data on Q2 2015:

- Sales grew 8 percent to €3.5 billion; pleasing volume growth and selling prices up overall year-on-year
- Adjusted EBITDA above strong first quarter at €661 million
- All three chemical segments posted better results than in the first quarter
- Adjusted EBITDA margin at a very good level of 18.8 percent
- Adjusted net income rose 70 percent to €307 million

### Key data on H1 2015:

- Considerable improvement in adjusted EBITDA to €1.3 billion (+40 percent)
- Three-quarters of the 22 business lines posted higher earnings than in the prior-year period
- Outlook for 2015 raised: sales expected to be around €13.5 billion (2014: €12.9 billion), with adjusted EBITDA around €2.4 billion (2014: €1.9 billion)

Essen. "Evonik has posted another strong quarterly result," said Klaus Engel, Chairman of the Executive Board of Evonik Industries AG, today, when the Group presented its key financial data for the second quarter and first half of 2015. "The successful business trend continued in the second quarter. It is especially pleasing to report that all three chemical segments improved their results further compared with the already very good first quarter."

At Group level as well, sales and adjusted EBITDA rose further compared with the first quarter of 2015 and were well above the prior-year figures. Global demand for Evonik's products was good and volumes increased further compared with the second quarter of 2014. In view of the continued strong business performance, Evonik is raising its outlook for the full year.

**Evonik Industries AG**  
Rellinghauser Straße 1-11  
45128 Essen  
Germany  
Phone +49 201 177-01  
Telefax +49 201 177-3475  
www.evonik.com

**Supervisory Board**  
Dr. Werner Müller, Chairman  
**Executive Board**  
Dr. Klaus Engel, Chairman  
Dr. Ralph Sven Kaufmann  
Christian Kullmann  
Thomas Wessel  
Ute Wolf

Registered office Essen  
Registered court  
Essen local court  
Commercial registry B 19474  
VAT ID no. DE 811160003

### Evonik Group: key data for Q2/H1

Sales grew 8 percent to €3,519 million in the second quarter of 2015, and also by 8 percent to €6,944 million in the first six months of the year. Adjusted EBITDA increased by 40 percent to €661 million in the second quarter, and by 40 percent to €1,311 million in the first six months. This was principally due to the sustained good volume trend, partly as a result of the new capacity, and to higher selling prices and slightly lower raw material costs. The adjusted EBITDA margin rose to a very good level of 18.9 percent in the first six months (H1 2014: 14.5 percent). Adjusted net income, which reflects the development of operating earnings, increased by 70 percent to €307 million in the second quarter, and by 67 percent to €627 million in the first six months.

### Outlook for the year raised again

In view of the continued strong business trend, Evonik has raised its outlook for fiscal 2015 again: The company now expects to report sales of around €13.5 billion (2014: €12.9 billion) and adjusted EBITDA of around €2.4 billion (2014: €1,882 million). At the start of the fiscal year, it had assumed a slight increase in sales and earnings. Following the successful first quarter, Evonik raised its guidance for adjusted EBITDA to at least €2.2 billion.

### Segment performance

In the **Nutrition & Care** segment sales grew 27 percent to €1,248 million in the second quarter of 2015 (Q2 2014: €983 million), thanks to higher selling prices and positive currency effects. Adjusted EBITDA more than doubled to €381 million (Q2 2014: €186 million), driven by the improvement in prices and lower raw material costs. The adjusted EBITDA margin was excellent at 30.5 percent.

The **Resource Efficiency** segment registered stable selling prices and higher demand for its products in the second quarter. Sales rose 6 percent to €1,110 million, partly as a result of positive currency effects (Q2 2014: €1,043 million). Adjusted EBITDA improved 12 percent to €254 million (Q2 2014: €226 million) as a result of high capacity utilization and a slight drop in raw material prices. The adjusted EBITDA margin improved to a very good 22.9 percent.

In the **Performance Materials** segment, sales dropped 4 percent to €938 million in the second quarter. This was principally caused by persistently low selling prices. The reduction was checked by an upturn in volumes and positive currency effects. Adjusted EBITDA was €82 million, almost unchanged from the prior-year period (€83 million), partly due to lower raw material costs. The adjusted EBITDA margin was 8.7 percent, up from 8.5 percent in the second quarter of 2014.

## Evonik Group: Excerpt from the income statement

(in € million)	Q2 2015	Q2 2014	Change in %	H1 2015	H1 2014	Change in %
Sales	3,519	3,247	8	6,944	6,448	8
Adjusted EBITDA	661	471	40	1,311	936	40
Adjusted EBIT	486	321	51	971	639	52
Adjustments	122	-72		85	-90	
Financial result	-51	-63		-114	-147	
Income before income taxes, continuing operations	557	186	199	942	402	134
Income taxes	-133	-70		-249	-133	
Income after taxes, continuing operations	424	116	266	693	269	158
Income after taxes, discontinued operations	-5	26		-15	43	
Income after taxes	419	142	195	678	312	117
thereof attributable to non-controlling interests	1	3		4	7	
<b>Net income</b>	<b>418</b>	<b>139</b>	<b>201</b>	<b>674</b>	<b>305</b>	<b>121</b>
<b>Adjusted net income</b>	<b>307</b>	<b>181</b>	<b>70</b>	<b>627</b>	<b>375</b>	<b>67</b>

Prior-year figures restated

## Segment performance

	Sales Q2			Adjusted EBITDA Q2		
	2015 € million	2014 € million	Change in %	2015 € million	2014 € million	Change in %
Nutrition & Care	1,248	983	27	381	186	105
Resource Efficiency	1,110	1,043	6	254	226	12
Performance Materials	938	979	-4	82	83	-1
Services	211	223	-5	31	45	-31
Other operations	12	19	-	-87	-69	-
<b>Group</b>	<b>3,519</b>	<b>3,247</b>	<b>8</b>	<b>661</b>	<b>471</b>	<b>40</b>
	Sales H1			Adjusted EBITDA H1		
	2015 € million	2014 € million	Change in %	2015 € million	2014 € million	Change in %
Nutrition & Care	2,476	1,945	27	734	372	97
Resource Efficiency	2,233	2,042	9	498	447	11
Performance Materials	1,788	1,978	-10	154	163	-6
Services	419	454	-8	77	88	-13
Other operations	28	29	-	-152	-134	-
<b>Group</b>	<b>6,944</b>	<b>6,448</b>	<b>8</b>	<b>1,311</b>	<b>936</b>	<b>40</b>

Prior-year figures restated

### Employees by segment

	June 30, 2015	Dec. 31, 2014
Nutrition & Care	6,916	6,943
Resource Efficiency	8,231	7,835
Performance Materials	4,245	4,353
Services	12,907	13,173
Other operations	888	937
<b>Continuing operations</b>	<b>33,187</b>	<b>33,412</b>
Discontinued operations	-	171
<b>Group</b>	<b>33,187</b>	<b>33,412</b>

### Company information

Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik's corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms.

Evonik is active in over 100 countries around the world. In fiscal 2014 more than 33,000 employees generated sales of around €12.9 billion and an operating profit (adjusted EBITDA) of about €1.9 billion.

### Disclaimer

In so far as forecasts or expectations are expressed in this Investor Relations News or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.